Syntekabio Inc. (226330)

Overview

SyntekaBio, Inc. is a pioneering company in the intersection of genomic big data and artificial intelligence (AI) aimed at the advancement of drug discovery. Leveraging a powerful AI drug development platform known as DeepMatcher, SyntekaBio is at the forefront of creating innovative drug candidates. This platform is distinctive for its integration of new drug development technologies with genomic big data approaches. Founded in 2009 and based in Daejeon, South Korea, the company specializes in identifying biomarkers for individual cancer drug screening, disease susceptibility through immunotyping, pharmacogenomic typing, and the prediction of adverse drug effects using multi-omics information. Additionally, SyntekaBio is advancing in the development of new antigen prediction technologies, instrumental in the enhancement of therapeutic vaccines and cell therapy products, as well as in the prediction of antibody therapeutics.

Products and Services

• DeepMatcher AI Platform:

  This advanced AI drug development platform stands at the core of SyntekaBio's innovative approach, combining novel drug development technologies with genomic big data. It is engineered to streamline the discovery of new drug candidates by exploiting biomarker identification for precision medicine, particularly in cancer treatment.

• Cancer Drug Screening and Disease Susceptibility Assessments:

  Utilizing its genomic big data capabilities, SyntekaBio offers comprehensive screening services for individual cancer drugs, alongside assessments for disease susceptibility. These services are grounded in the identification of biomarkers through immunotyping and pharmacogenomic typing, aiming to personalize treatment and enhance patient outcomes.

• Prediction of Drug Adverse Effects:

  Through the analysis of multi-omics information, SyntekaBio is adept at predicting potential adverse effects of drug candidates. This predictive capability is essential in the early stages of drug development, facilitating the design of safer therapeutic options.

• Antigen Prediction Technology for Therapeutic Vaccines and Cell Therapy Products:

  Recognizing the critical role of antigens in effective immune responses, SyntekaBio is developing cutting-edge technology for new antigen prediction. This technology is envisaged to significantly advance the development of therapeutic vaccines and cell therapy products, offering new avenues for treatment.

• Prediction of Antibody Therapeutics:

  The company is also pioneering in the prediction of antibody therapeutics, leveraging its technological and data analytic capabilities. This effort is aligned with the broader aim of enhancing the precision and effectiveness of antibody-based therapies.